<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01800812</url>
  </required_header>
  <id_info>
    <org_study_id>BARDOU PHRC R 2002</org_study_id>
    <nct_id>NCT01800812</nct_id>
  </id_info>
  <brief_title>Effects of OM-174 in Adult Patients With Solid Tumors</brief_title>
  <acronym>OM-174</acronym>
  <official_title>Phase One Study With Direct Individual Benefit: Effects of OM-174 in Adult Patients With Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <brief_summary>
    <textblock>
      Methods Patients received OM-174 twice weekly for a total of 5, 10 or 15 injections of either
      600, 800 or 1000 µg/m². Pharmacokinetic analysis and cytokine dosages were performed. Natural
      Killer cells activity and toll-like receptors 4 polymorphism analysis were also performed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occurrence of any adverse event</measure>
    <time_frame>up to 8 weeks</time_frame>
  </primary_outcome>
  <enrollment>27</enrollment>
  <condition>Solid Tumors</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Injections of OM-174</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with a histologically proven solid tumor, refractory to conventional treatment
             or for which no such treatment existed.

          -  At least one month since the last chemotherapy

          -  Life expectancy above 3 months

          -  Written informed consent

          -  Age above 18

        Exclusion Criteria:

          -  Patient's refusal

          -  Infection

          -  Brain metastasis

          -  Autoimmune disease

          -  Regular use of steroids

          -  Patient included in another protocol

          -  Chemotherapy or radiotherapy less than 6 weeks ago

          -  Immunotherapy less than 8 weeks ago
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2013</study_first_submitted>
  <study_first_submitted_qc>February 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2013</study_first_posted>
  <last_update_submitted>February 26, 2013</last_update_submitted>
  <last_update_submitted_qc>February 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

